Intraprostatic steroidogenic enzymes - Response

Cancer Research

Volumn 70, Issue 20, 2010, Pages 8249-8250

  Hofland, Johannes ^a   Van Weerden, Wytske M ^a   Jenster, Guido ^a   Schröder, Fritz H ^a   De Jong, Frank H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CYTOCHROME P450C17; ENZYME;

ANDROGEN DEPRIVATION THERAPY; CANCER RESISTANCE; CASTRATION; CLINICAL TRIAL; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; STEROIDOGENESIS;

EID: 78049280619     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2476     Document Type: Letter

References (6)

1. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
2. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase 1/2, open-label study. ASCO Meeting, 2010, Chicago, Illinois.
3. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
4. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008;68:6407-15.
5. Hofland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010;70:1256-64.
6. van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992;50:857-61.